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Lymphatic mapping was introduced to the medical
community as an addition to the armamentarium of
breast cancer management strategies just over a
decade ago.1,2 The biological plausibility of sentinel
node biopsy is based on the rationale that we can
replicate the pathway that would be traversed by
cancer cells from a primary breast tumor through
intramammary lymphatic channels en route to
implantation in the first nodal recipients of metasta-
sis. Early studies involved sentinel lymphadenectomy
performed with a concomitant axillary lymph node
dissection (ALND) so that accuracy rates could be
defined. Within the following 5 years, identification
rates in excess of 95% and false-negative rates of
<5% were being consistently reported by numerous
investigators internationally.3–7 These promising re-
sults led to the acceptance of a cancer-free sentinel
lymph node as a reliable means of identifying the
node-negative patient who could be spared the mor-
bidity of a standard ALND. In this issue of Annals of
Surgical Oncology, two reports8,9 serve as reminders
that while we continue to search for ways that we can
revise and improve sentinel node biopsy algorithms,
we must remember the ultimate goals of axillary
surgery in breast cancer patients: the accurate deter-
mination of nodal status for prognostic value and
regional control of disease. In the studies reported
herein, Degnim et al.9 have systematically evaluated
whether selected patients can avoid the allergenic
risks of blue dye mapping, and Fan et al.8 have
looked at their institutions outcome experience after
sentinel lymphadenectomy.
Initial mapping experiences included rigorous
attention to technical and anatomical details. The
blue dye and/or radioactive label was injected perit-
umorally, and after waiting some prespecified inter-
val, the patient would undergo axillary exploration.
Blue dyes were injected during surgery, approxi-
mately 5 minutes before sentinel node dissection.
Radioactive isotopes were injected peritumorally, and
the timing of the surgery was based on subsequent
lymphoscintigraphy, which was frequently performed
on a sequential basis until sentinel uptake was iden-
tified on a preoperative scan. These techniques were
mechanistically sound; however, they became logis-
tically burdensome as the volume of mapping cases
increased. Patients with nonpalpable tumors fre-
quently required additional image-guided localization
procedures to facilitate injection of the mapping la-
bel, and surgical schedules were disrupted by the
unpredictability of lymphoscintigraphy results: up-
take in a nodal basin might occur within 30 minutes,
or it might require several hours. It was therefore
inevitable that variations in technique would be ex-
plored to improve the efficiency and ease of incor-
porating lymphatic mapping cases into busy
operating room caseloads.
Some of the first variations in mapping technique
involved alternative injection sites, such as dermal
injections overlying the breast tumor10,11 or subareo-
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lar injections.12,13 These approaches made it easier to
handle nonpalpable lesions. Other variations ad-
dressed consideration of alternative isotope strategies,
such as abandoning the preoperative lymphoscinti-
gram14 or performing isotope injections on the day
before surgery.15,16 These strategies facilitated inte-
gration of mapping cases into the main surgical
schedules. A meta-analysis of the worldwide experi-
ence with sentinel lymph node biopsy performed in
conjunction with a standard ALND17 validated the
conventional routine for lymphatic mapping, but
many of the studies evaluating novel mapping tech-
niques that have been reported in the more recent
literature focused on the ability to identify a sentinel
lymph node; the false-negative rates associated with
these alternative methods are more uncertain because
the completion ALND is not performed consistently
in these series. It is therefore conceivable that we are
missing some finite proportion of false-negative cases
with these alternative mapping strategies, although
this proportion is likely to be very small.
The absolute number of sentinel lymph nodes that
should be removed has also been questioned. Al-
though the average lymphatic mapping case will
identify two or three sentinel nodes, it is not
uncommon for patients to have very exuberant up-
take of the mapping label, resulting in five or more
sentinel nodes. Because avoidance of extensive sur-
gery, thereby minimizing the risk of lymphedema
secondary to impaired lymphatic drainage, is a major
goal of the sentinel node procedure, it is appropriate
to question whether surgical attention can be focused
on a fixed, limited number of sentinel nodes.
McCarter et al.18 addressed this question in a
Memorial Sloan-Kettering review of patients with
four or more sentinel lymph nodes; this subset com-
prised 15% of their sentinel lymph node dataset.
When metastatic disease was present in this category
of multiple sentinel node cases, it was identified in the
first three sentinel nodes resected for the vast majority
(98%); however, in a small proportion of cases,
metastatic disease was detected only with aggressive
resection of all sentinel nodes beyond the first three
encountered.
Degnim et al.9 have evaluated the question of
whether blue dye–related morbidity can be avoided
by relying on isotope mapping alone in cases in which
the preoperative lymphoscintigraphy identifies ax-
illary radioactivity. This study of University of
Michigan breast cancer patients demonstrated that
even when isotope mapping was successful, the met-
astatic disease was detected in sentinel nodes identi-
fied by their uptake of blue dye only in 2.5% of cases.
This suggests that although the overwhelming
majority of metastatic sentinel nodes will be identified
with standard isotope mapping, a well-defined subset
of cases will be understaged if blue dye is excluded
from the procedure.
The results of Fan et al.8 demonstrating an axillary
relapse rate of only 3.3% in breast cancer patients
whose axillary operation was limited to the resection
of negative sentinel lymph nodes are modestly reas-
suring. However, the traditional ALND will usually
keep axillary failure rates below 2%. It is therefore
critical that individual breast surgical oncology pro-
grams continue to track their own outcome results
over time, especially if variations in the lymphatic
mapping methodology have been introduced into
local practices. Small incremental increases in risk for
missed metastatic sentinel lymph nodes may be
cumulative over time, and the effect of these effects
can be determined only with ongoing, long-term
follow-up.
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